N-phenethyl-3-(trifluoromethyl)benzamide | 135726-92-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-phenethyl-3-(trifluoromethyl)benzamide
• 英文别名: N-(2-phenylethyl)-3-(trifluoromethyl)benzamide
• CAS: 135726-92-0
• 化学式: C₁₆H₁₄F₃NO
• mdl: MFCD00779725
• 分子量: 293.288
• InChiKey: ZEFVLBILODMYHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-phenethyl-3-(trifluoromethyl)benzamide 在 platinum(IV) oxide 、 四磷十氧化物 、 氢气 、 三氯氧磷 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 乙醇 为溶剂， 反应 18.0h， 生成 1-(3-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  基于四氢异喹啉的组蛋白脱乙酰基酶8选择性抑制剂的设计，合成和生物学评估

  摘要：

  组蛋白脱乙酰基酶8（HDAC8）是用于多种治疗应用的有希望的药物靶标。在这里，我们描述了基于C1取代的四氢异喹啉（TIQ）的新型HDAC8抑制剂系列的建模，设计，合成和生物学评估。配体结合后熵损失的最小化以及结合位点独特的HDAC8“开放”构象的使用产生了成功的策略，可同时提高HDAC8的效力和选择性。基于TIQ的3g和3n分别比HDAC1表现出最高的82和55 nM HDAC8效能以及330倍和135倍的选择性。与其他I类同工型的选择性相当或更好，而II类HDAC同工型HDAC6的抑制在10μM下低于50％。3g和3g的细胞毒性3n个在神经母细胞瘤细胞系中进行了评价，并3N显示类似或比PCI-34051的更好的浓度依赖性细胞毒性。在SH-SY5Y细胞中证实了3g和3n的选择性，因为它们都不增加组蛋白H3和α-微管蛋白的乙酰化。新型TIQ化学型的发现为开发用于治疗应用的HDAC8选择性抑制剂铺平了道路。

  DOI：

  10.1021/acsmedchemlett.7b00126
• 作为产物：
  描述：

  3-三氟甲基苯甲酸 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 生成 N-phenethyl-3-(trifluoromethyl)benzamide
  参考文献：
  名称：

  基于四氢异喹啉的组蛋白脱乙酰基酶8选择性抑制剂的设计，合成和生物学评估

  摘要：

  组蛋白脱乙酰基酶8（HDAC8）是用于多种治疗应用的有希望的药物靶标。在这里，我们描述了基于C1取代的四氢异喹啉（TIQ）的新型HDAC8抑制剂系列的建模，设计，合成和生物学评估。配体结合后熵损失的最小化以及结合位点独特的HDAC8“开放”构象的使用产生了成功的策略，可同时提高HDAC8的效力和选择性。基于TIQ的3g和3n分别比HDAC1表现出最高的82和55 nM HDAC8效能以及330倍和135倍的选择性。与其他I类同工型的选择性相当或更好，而II类HDAC同工型HDAC6的抑制在10μM下低于50％。3g和3g的细胞毒性3n个在神经母细胞瘤细胞系中进行了评价，并3N显示类似或比PCI-34051的更好的浓度依赖性细胞毒性。在SH-SY5Y细胞中证实了3g和3n的选择性，因为它们都不增加组蛋白H3和α-微管蛋白的乙酰化。新型TIQ化学型的发现为开发用于治疗应用的HDAC8选择性抑制剂铺平了道路。

  DOI：

  10.1021/acsmedchemlett.7b00126

文献信息

• Base-Mediated Anti-Markovnikov Hydroamidation of Vinyl Arenes with Arylamides
  作者：Ayushee、Monika Patel、Priyanka Meena、Kousar Jahan、Prasad V. Bharatam、Akhilesh K. Verma

  DOI：10.1021/acs.orglett.0c04084

  日期：2021.1.15

  anti-Markovnikov hydroamidation of vinyl arenes with arylamides to furnish the arylethylbenzamides with excellent chemo- and regioselectivity. The reaction tolerates an extensive variety of functional groups and has been successfully extended with electronically varied handles, aminobenzamides, electron-rich/electron-deficient heterocyclic amides, and vinyl arenes to afford the hydroamidated products.

  我们研究了乙烯基芳烃与芳基酰胺的分子间抗Markovnikov加氢酰胺化的碱促进方案，以提供具有优异的化学和区域选择性的芳基乙基苯甲酰胺。该反应可耐受多种官能团，并已成功地扩展了电子形式的手柄，氨基苯甲酰胺，富电子/缺电子的杂环酰胺和乙烯基芳烃，以提供加氢酰胺化产物。观察到酰胺基优于胺具有出色的化学选择性。氘标记研究和对照实验充分支持了所提出的溶剂机理和重要作用。
• Heteroaryl and benzyl amide compounds
  申请人：Conte Aurelia

  公开号：US20070185058A1

  公开（公告）日：2007-08-09

  Compounds of formula I wherein R 1 , R 2 , R 4 , R 5 , A, B, D and n are as defined, and pharmaceutically acceptable salts thereof, processes for their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.

  式I中的化合物，其中R1、R2、R4、R5、A、B、D和n的定义如上，并其药用盐，其制备方法，它们作为药物的用途以及包含它们的药物组合物。
• Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model
  作者：Maud Bollenbach、Claire Lugnier、Mélanie Kremer、Eric Salvat、Salim Megat、Frédéric Bihel、Jean-Jacques Bourguignon、Michel Barrot、Martine Schmitt

  DOI：10.1016/j.ejmech.2019.05.026

  日期：2019.9

  Neuropathic pain is a chronic pain caused by a lesion or disease affecting the somatosensory nervous system. To date, no specific treatment has been developed to cure this pain. Antidepressants and anticonvulsant drugs are used, but they do not demonstrate universal efficacy, and they often cause detrimental adverse effects. Some studies highlighted the efficacy of sildenafil, a well-known inhibitor of phosphodiesterase 5 (PDE5, (IC50=3.3 nM)), in models of pain. Based on these results, we focused our attention on MY 5445, another known PDE5 inhibitor. Homologues, isosteres and structural analogues of MY 5445 were designed and all synthesized compounds were evaluated for their inhibitory activity toward PDE5. Selectivity profiles towards other PDE1-4 isoenzymes, water solubility and stability in acidic medium of the most potent PDE5 inhibitors were determined and the aminophthalazine 16h and its mimetic 41n (3-aminoindazole) were evaluated in comparison to MY 5445 (4b) in vivo in a model of neuropathic pain induced by sciatic nerve cuffing in mice (3 and 0.5 mg/kg, ip twice a day). Both compounds showed the same efficacy on neuropathic allodynia as MY 5445, and thus produced a significant relief of mechanical hypersensitivity after 12 days of treatment. (C) 2019 Elsevier Masson SAS. All rights reserved.
• Design, synthesis and structure–activity relationship of novel inhibitors against H5N1 hemagglutinin-mediated membrane fusion
  作者：Zhibo Zhu、Runming Li、Gaokeng Xiao、Zhipeng Chen、Jie Yang、Qiuhua Zhu、Shuwen Liu

  DOI：10.1016/j.ejmech.2012.08.041

  日期：2012.11

  We reported previously that a small molecule named CL-385319 could inhibit H5N1 influenza virus infection by targeting hemagglutinin, the envelope protein mediating virus entry. In the present study, a novel series of derivatives focused on the structural variation of CL-385319 were synthesized as specific inhibitors against the H5 subtype of influenza A viruses. These small molecules inhibited the low pH-induced conformational change of hemagglutinin, thereby blocking viral entry into host cells. Compound 11 was the most active inhibitor in this series with an IC50 of 0.22 mu M. The structure activity relationships analysis of these compounds showed that the 3-fluoro-5-(trifluoromethyl)benzamide moiety was very important for activity, and the -F group was a better substituent group than -CF3 group in the phenyl ring. The inhibitory activity was sensitive to the benzamide because the oxygen and hydrogen of the amide served as H-bond acceptor and donor, respectively. (C) 2012 Elsevier Masson SAS. All rights reserved.
• BIR DOMAIN BINDING COMPOUNDS
  申请人：Jarvis Scott

  公开号：US20100292269A1

  公开（公告）日：2010-11-18

  The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R 1 , R 1a , R 2 , R 2a , R 3 , A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer